Dr. Jeffrey Cossman is Independent Director of the Company. He was a founder of, and served as Chief Executive Officer and Chairman of the Board at, United States Diagnostic Standards, Inc. from 2009 to 2014 and served as a member of the board of directors of The Personalized Medicine Coalition from 2008 to 2014. Prior to that, he served as Chief Scientific Officer and a member of the board of directors of The Critical Path Institute and as Medical Director of Gene Logic, Inc.; he was Professor and Chairman of the Department of Pathology at Georgetown University Medical Center and held the Oscar Benwood Hunter Chair of Pathology at Georgetown; and he served as Senior Investigator in Hematopathology at the National Cancer Institute. He is currently a medical advisor to Epigenomics AG. Dr. Cossman holds a B.S. from the University of Michigan and an M.D. from the University of Michigan Medical School. He is board-certified in pathology and trained in pathology and hematopathology at the University of Michigan, Stanford University and the National Institutes of Health.
Jeffrey's mailing address filed with the SEC is C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN, CT, 06511.
Over the last 7 years, insiders at Precipio Inc have traded over $449,545 worth of Precipio Inc stock and bought 88,796 units worth $87,860 . The most active insiders traders include Randal J Kirk, Ronald Asbury Andrews és Richard A Sandberg. On average, Precipio Inc executives and independent directors trade stock every 54 days with the average trade being worth of $44,781. The most recent stock trade was executed by Richard A Sandberg on 20 January 2023, trading 20,000 units of PRPO stock currently worth $15,600.
precipio is a cancer diagnostics reference laboratory, delivering the latest in advanced diagnostics and personalized medicine. our goal is to assist oncologists in providing the best care for their patients. at the intersection of academia, cancer research, and diagnostics, we connect physicians with world-renown pathologists at the yale school of medicine. at precipio, our customers and their patients benefit from the most accurate, expert diagnosis. we provide our customers exclusive access to some of the most innovative tests in the field of molecular diagnostics, developed through cutting edge research, and the ongoing pursuit and refinement of the science of personalized medicine.
Precipio Inc executives and other stock owners filed with the SEC include: